South Korea
· Delayed Price · Currency is KRW MiCo BioMed Statistics
Total Valuation
MiCo BioMed has a market cap or net worth of KRW 63.90 billion. The enterprise value is 76.71 billion.
| Market Cap | 63.90B |
| Enterprise Value | 76.71B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MiCo BioMed has 43.56 million shares outstanding. The number of shares has increased by 86.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 43.56M |
| Shares Change (YoY) | +86.40% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 0.00% |
| Float | 34.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.23 |
| PB Ratio | 4.06 |
| P/TBV Ratio | 6.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.56 |
| EV / Sales | 9.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.77 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.38 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.96 |
| Interest Coverage | -14.73 |
Financial Efficiency
Return on equity (ROE) is -290.20% and return on invested capital (ROIC) is -52.77%.
| Return on Equity (ROE) | -290.20% |
| Return on Assets (ROA) | -38.91% |
| Return on Capital (ROIC) | -52.77% |
| Revenue Per Employee | 116.94M |
| Profits Per Employee | -422.64M |
| Employee Count | 71 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -22.63% |
| 50-Day Moving Average | 1,620.18 |
| 200-Day Moving Average | 1,624.42 |
| Relative Strength Index (RSI) | 45.70 |
| Average Volume (20 Days) | 3,540,231 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MiCo BioMed had revenue of KRW 8.30 billion and -30.01 billion in losses. Loss per share was -732.92.
| Revenue | 8.30B |
| Gross Profit | -8.45B |
| Operating Income | -25.91B |
| Pretax Income | -30.09B |
| Net Income | -30.01B |
| EBITDA | -23.79B |
| EBIT | -25.91B |
| Loss Per Share | -732.92 |
Balance Sheet
The company has 4.32 billion in cash and 15.41 billion in debt, giving a net cash position of -11.09 billion or -254.56 per share.
| Cash & Cash Equivalents | 4.32B |
| Total Debt | 15.41B |
| Net Cash | -11.09B |
| Net Cash Per Share | -254.56 |
| Equity (Book Value) | 17.45B |
| Book Value Per Share | 361.26 |
| Working Capital | 6.14B |
Cash Flow
In the last 12 months, operating cash flow was -15.31 billion and capital expenditures -765.47 million, giving a free cash flow of -16.08 billion.
| Operating Cash Flow | -15.31B |
| Capital Expenditures | -765.47M |
| Free Cash Flow | -16.08B |
| FCF Per Share | -369.09 |
Margins
| Gross Margin | -101.77% |
| Operating Margin | -312.10% |
| Pretax Margin | -362.35% |
| Profit Margin | n/a |
| EBITDA Margin | -286.55% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MiCo BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -86.40% |
| Shareholder Yield | -86.40% |
| Earnings Yield | -49.96% |
| FCF Yield | -25.16% |
Stock Splits
The last stock split was on November 16, 2023. It was a forward split with a ratio of 1.199978.
| Last Split Date | Nov 16, 2023 |
| Split Type | Forward |
| Split Ratio | 1.199978 |
Scores
MiCo BioMed has an Altman Z-Score of -5.27. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.27 |
| Piotroski F-Score | n/a |